natgillin/translations-raw huggingface dataset:
Hos patienter med let til moderat nedsat leverfunktion på grund af cirrose, bør indinavirdosis reduceres til 600 mg hver 8. time.
In patients with mild–to–moderate hepatic impairment due to cirrhosis, the dose of indinavir should be reduced to 600 mg every 8 hours.
Hos patienter med let til moderat nedsat nyrefunktion (kreatininclearance på  30–80 ml/min) sammenlignet med dem, der havde normal nyrefunktion (kreatininclearance > 80 ml/min), var de hyppigst indberettede bivirkninger korrigeret for placebo: forstoppelse (8 % mod 4 %), svimmelhed (7 % mod 5 %) og kvalme (4 % mod 2 %).
In patients with mild or moderate renal impairment (creatinine clearance  30–80 ml/min) compared to those with normal renal function (creatinine clearance > 80 ml/min), the most commonly reported events and their placebo-corrected frequencies included: constipation (8% versus 4%), dizziness (7% versus 5%), and nausea (4% versus 2%).
Hos patienter med let til moderat nedsat nyrefunktion er en 3 gange større AUC- værdi for hydrochlorthiazid observeret.
In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed.
Hos patienter med let til moderat nedsat nyrefunktion kan en støddosis på 200 mg overvejes, dog bør yderligere dosistitrering (>200 mg/dag) ske med forsigtighed.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered but further dose titration (>200 mg daily) should be performed with caution.
Hos patienter med let til moderat nedsat nyrefunktion kan en støddosis på 200 mg overvejes, dog bør yderligere dosistitrering (>200 mg/dag) ske med forsigtighed.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration (>200 mg daily) should be performed with caution.
Hos patienter med let til moderat nedsat nyrefunktion kan en støddosisdosis på 200 mg overvejes, dog bør yderligere dosistitrering (>200 mg/dag) ske med forsigtighed.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration (>200 mg daily) should be performed with caution.
Hos patienter med lettere nedsat leverfunktion (Child-Pugh A) øgedes den gennemsnitlige AUC og Cmax henholdsvis 17% og 22% sammenlignet med en kontrolgruppe med raske forsøgspersoner.
In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased 17% and 22% respectively, compared to healthy control subjects.
Hos patienter med lever- eller nyreproblemer skal lægen overvåge blodets koagulationsevne med henblik på en eventuel justering af doseringen.
In patients who have liver or kidney problems, the doctor will monitor blood clotting to see if the dosages may need to be adjusted.
Hos patienter med leverinsufficiens (Child-Pugh A, B eller C) blev der efter gentagen dosering af fluticasonfuroat/vilanterol i 7 dage set en stigning i systemisk eksponering af fluticasonfuroat (op til 3 gange større målt ved AUC(0-24)) sammenlignet med raske personer.
Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (up to three-fold as measured by AUC(0–24)) in subjects with hepatic impairment (Child-Pugh A, B or C) compared with healthy subjects.
Hos patienter med leverinsufficiens øgedes eksponeringen med 9 til 25%.
In patients with hepatic impairment, exposures were elevated by 9 to 25%.
Hos patienter med leverproblemer (herunder hepatitis B- eller C-infektioner) kan Telzir øge risikoen for leverskade.
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Telzir.
Hos patienter med leversvigt er dosisjustering ikke nødvendig, da ca.
Dose adjustment in patients with hepatic failure is not required, as approx.
Hos patienter med lidelsen øjentørhed, som er en tilstand, der kan ses som havende en inflammatorisk immunologisk mekanisme, absorberes ciclosporin efter okulær administration ind i T-lymfocyt- infiltraterne i cornea og conjunctiva og inaktiverer calcineurinfosfatase.
In patients with dry eye disease, a condition that may be considered to have an inflammatory immunological mechanism, following ocular administration, ciclosporin is passively absorbed into T- lymphocyte infiltrates in the cornea and conjunctiva and inactivates calcineurin phosphatase.
hos patienter med lidelser, der
exercised in patients with
Hos patienter med lungekræft bør lægen undersøge kræften for at kontrollere, om kræftcellerne producerer PD-L1 proteinet, inden denne indleder behandlingen.
For patients with lung cancer, doctors should test the tumours to check if the cancer cells produce the PD-L1 protein before starting treatment.
Hos patienter med maniske eller blandede episoder af bipolar sindslidelse havde olanzapin, administreret oralt, overlegen effekt i reduktion af maniske symptomer over 3 uger i forhold til placebo og valproat.
In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
Hos patienter med maniske eller blandede episoder af manio-depressiv sygdom havde olanzapin overlegen effekt i reduktion af maniske symptomer over 3 uger i forhold til placebo og valproat.
In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
Hos patienter med mantelcellelymfom er lenalidomid forbundet med en højere forekomst af grad 3 og 4 neutropeni (43,7 % hos lenalidomidbehandlede patienter sammenlignet med 33,7 % i kontrolarmen i fase II-studiet).
In mantle cell lymphoma patients, lenalidomide is associated with a higher incidence of grade 3 or 4 neutropenia (43.7% in lenalidomide-treated patients compared with 33.7% in patients in the control arm in the Phase II study).
Hos patienter med mantelcellelymfom er lenalidomid forbundet med en højere forekomst af grad 3 og 4 neutropeni (43,7 % hos lenalidomidbehandlede patienter, sammenlignet med 33,7 % i kontrolarmen i fase II-studiet).
In mantle cell lymphoma patients, lenalidomide is associated with a higher incidence of grade 3 or 4 neutropenia (43.7% in lenalidomide-treated patients compared with 33.7% in patients in the control arm in the Phase II study).
Hos patienter med mantelcellelymfom skal monitoreringsfrekvensen være hver 2. uge i cyklus 3 og 4 og derefter ved start af hver cyklus.
In mantle cell lymphoma patients, the monitoring scheme should be every 2 weeks in Cycles 3 and 4, and then at the start of each cycle.
Hos patienter med mantelcellelymfom var den gennemsnitlige tid, inden sygdommen blev værre 37, 6 uger hos dem, der blev behandlet med Revlimid, sammenlignet med 22,7 uger hos dem, der fik andre behandlinger.
For patients with mantle cell lymphoma, the average time before the disease got worse was 37.6 weeks in those treated with Revlimid, compared with 22.7 weeks in those given other treatments.
Hos patienter med markant volumen- og saltdepletering (f.eks. patienter med opkastninger, diarré, eller patienter, som har taget høje doser diuretika), kan der forekomme symptomatisk hypotension efter initiering af behandling med Edarbi.
In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Edarbi.
Hos patienter med MCL (studie LYM-3002) var der en højere forekomst (56,7 % versus 5,8 %) af grad ≥ 3-trombocytopeni i bortezomib-armen (BzmbR-CAP) sammenlignet med non-bortezomib- armen (rituximab, cyclophosphamid, doxorubicin, vincristin og prednison [R-CHOP]).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BzmbR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
Hos patienter med mild (kreatinin-clearance 50 til 80 ml/min) eller moderat (kreatinin-clearance 30 til 50 ml/min.) nedsat nyrefunktion, var clearance af exenatid let reduceret sammenlignet med clearance hos personer med normal nyrefunktion (13 % reduktion for mild og 36 % for moderat nedsat nyre- funktion).
In patients with mild (creatinine clearance 50 to 80 ml/min) or moderate renal impairment (creatinine clearance 30 to 50 ml/min), exenatide clearance was mildly reduced compared to clearance in individuals with normal renal function (13% reduction in mild and 36% reduction in moderate renal impairment).
Hos patienter med mild til moderat levercirrose (Child-Pugh-klasse A og B), der får voriconazol, anbefales standardinitialdosis, mens vedligeholdelsesdosis halveres (se pkt.
It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole (see section 5.2).
Hos patienter med minimum et delvist respons på Humira 40 mg ugentlig ved uge 12 var HiSCR-raten ved uge 36 højere hos patienter, der fortsatte ugentlig Humira, end hos de patienter, hvor doseringshyppigheden blev reduceret til hver anden ugen eller behandlingen afbrudt (Se tabel 15).
In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week 36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 15).
Hos patienter med minimum et delvist respons på Humira 40 mg ugentlig ved uge 12 var HiSCR-raten ved uge 36 højere hos patienter, der fortsatte ugentlig Humira, end hos de patienter, hvor doseringshyppigheden blev reduceret til hver anden ugen eller behandlingen afbrudt (Se tabel 17).
In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week 36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 17).
Hos patienter med moderat eller svær leverinsufficiens (Child-Pugh B eller C) blev der efter gentagen dosering med oral inhalation af fluticasonfuroat/vilanterol i 7 dage set en stigning i den systemiske eksponering af fluticasonfuroat (gennemsnitligt 2 gange større målt ved AUC(0–24)) sammenlignet med raske frivillige.
Following repeat dosing of orally inhaled fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (on average two-fold as measured by AUC(0–24)) in subjects with moderate or severe hepatic impairment (Child-Pugh B or C) compared with healthy subjects.
Hos patienter med moderat eller svært nedsat nyrefunktion bør den daglige dosis nedsættes til det halve.
The daily dose should be reduced by half in patients with moderate or severely reduced kidney function.
Hos patienter med moderat hyperkalcæmi (albuminkorrigeret serum-calcium < 3 mmol/l eller < 12 mg/dl) er 2 mg en effektiv dosis.
In patients with moderate hypercalcaemia (albumin- corrected serum calcium <3 mmol/l or <12 mg/dl) 2 mg is an effective dose.
Hos patienter med moderat hyperkalcæmi (albuminkorrigeret serum-calcium <3 mmol/l eller <12 mg/dl) er 2 mg en effektiv dosis.
In patients with moderate hypercalcaemia (albumin-corrected serum calcium <3 mmol/l or <12 mg/dl) 2 mg is an effective dose.
Hos patienter med moderat leverinsufficiens var eksponeringen for ospemifen og
In patients with moderate hepatic impairment the exposure of ospemifene and
Hos patienter med moderat nedsat leverfunktion (dvs.
In subjects with moderate hepatic impairment (i.e.
Hos patienter med moderat nedsat leverfunktion kan en nedsat dosis på 150 mg én gang dagligt derfor anbefales.
Therefore in patients with moderate hepatic impairment, a reduced dose of 150 mg once daily is recommended.
Hos patienter med moderat nedsat leverfunktion kan en nedsat dosis på 50 mg én gang dagligt derfor anbefales hos patienter i alderen 2 år og derover med en kropsvægt under 14 kg og 75 mg én gang dagligt hos patienter med en kropsvægt fra 14 kg til under 25 kg.
Therefore in patients with moderate hepatic impairment, a reduced dose of 50 mg once daily is recommended in patients aged 2 years and older with body weight less than 14 kg and 75 mg once daily for those with body weight 14 kg to less than 25 kg.
Hos patienter med moderat nedsat nyrefunktion (anslået kreatininclearance ≥30 ml/min og 50 ml/min) var vareniclinniveauet øget 1,5 gange sammenlignet med patienter med normal nyrefunktion (anslået kreatininclearance >80 ml/min).
In patients with moderate renal impairment (estimated creatinine clearance  30 ml/min and  50 ml/min), varenicline exposure increased 1.5- fold compared with subjects with normal renal function (estimated creatinine clearance > 80 ml/min).
Hos patienter med moderat nedsat nyrefunktion (GFR 30-59 ml/min) skal infusionshastigheden reduceres til 1,4 mg/kg/t.
In patients with moderate renal impairment (GFR 30-59 ml/ min) the infusion rate should be reduced to 1.4 mg/kg/h.
Hos patienter med moderat nedsat nyrefunktion (kreatinin-clearance 30- 49 ml/min) er daglig dosis 10 mg pr. dag.
In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) daily dose should be 10 mg per day.
Hos patienter med moderat nedsat nyrefunktion (kreatinin-clearance 30- 49 ml/min) er daglig dosis 10 mg pr. dag.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Hos patienter med moderat nedsat nyrefunktion (kreatinin-clearance 30-49 ml/min) er daglig dosis 10 mg (1 ml opløsning, hvilket svarer til to tryk på pumpen).
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations).
Hos patienter med moderat nedsat nyrefunktion (kreatininclearance 30 – 49 ml/min) er daglig dosis 10 mg pr. dag.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Hos patienter med moderat nedsat nyrefunktion (kreatininclearance 30-49 ml/min) eller svært nedsat nyrefunktion (kreatininclearance 15-29 ml/min) anbefales følgende dosering:
In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dosage recommendations apply:
Hos patienter med moderat nedsat nyrefunktion (kreatininclearance = 30-50 ml/min) blev der opnået en hæmning på 100 % 24 timer efter administration af 2 mikrogram/kg/min.
In patients with moderate renal impairment, (creatinine clearance 30 – 50mL/min) 100% inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
Hos patienter med moderat nedsat nyrefunktion (kreatininclearance ≥ 30 til ≤ 50 ml/min) bør alogliptindosis halveres (12,5 mg én gang dagligt; se pkt.
For patients with moderate renal impairment (creatinine clearance ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered (12.5 mg once daily; see section 5.2).
Hos patienter med moderat nedsat nyrefunktion (kreatininclearance ≥ 30-< 50 ml/minut) skal der gives en intravenøs bolusinjektion på 180 mikrogram/kg efterfulgt af 1 mikrogram/kg/minut i kontinuerlig infusion i resten af behandlingsperioden.
In patients with moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min), an intravenous bolus of 180 microgram/kg should be administered followed by a continuous infusion dose of
Hos patienter med moderat nedsat nyrefunktion (kreatininclearance ≥ 30-< 50 ml/minut) skal der gives en intravenøs bolusinjektion på 180 mikrogram/kg efterfulgt af 1,0 mikrogram/kg/minut i kontinuerlig infusion i resten af behandlingsperioden.
In patients with moderate renal impairment (creatinine clearance ≥ 30 - < 50 ml/min), an intravenous bolus of 180 microgram/kg should be administered followed by a continuous infusion dose of
Hos patienter med moderat nedsat nyrefunktion kan lægen finde det nødvendigt at give en mindre dosis.
In patients with moderately reduced kidney function the doctor may need to reduce the dose.
Hos patienter med moderat nedsat nyrefunktion var forekomsten af nyrerelaterede bivirkninger den samme i alle behandlingsgrupperne: Zurampic 200 mg (12,7 %), Zurampic 400 mg (16,3 %) og placebo (13,3 %).
In patients with moderate renal impairment, the incidence of renal- related adverse reactions was similar across all treatment groups: Zurampic 200 mg (12.7%), Zurampic 400 mg (16.3%) and placebo (13.3%).
Hos patienter med moderat til svær nyreinsufficiens (kreatininclearance < 50 ml/minut) er clearance reduceret med cirka 50 % og steady- state plasmaværdier omtrent fordoblet.
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50 % and steady-state plasma levels are approximately doubled.
Hos patienter med moderat til svær nyreinsufficiens (kreatininclearance < 50 ml/minut) er clearance reduceret med cirka 50 % og steady- state plasmaværdier omtrent fordoblet.
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels are approximately doubled.
Hos patienter med moderat til svært nedsat nyrefunktion (CrCl 15 – 50 ml/min) er den anbefalede dosis 30 mg Lixiana en gang dagligt (se pkt.
In patients with moderate or severe renal impairment (CrCL 15 – 50 mL/min), the recommended dose is 30 mg Lixiana once daily (see section 5.2).
Hos patienter med moderate leverproblemer bør startdosis mindskes til 0,3 mg to gange dagligt, og den anbefalede maksimale dosis er 0,6 mg to gange dagligt.
In patients with moderate liver problems, the starting dose should be reduced to 0.3 mg twice a day and the maximum recommended dose is 0.6 mg twice a day.
Hos patienter med multipelt myelom kan risikoen for nedsat nyrefunktion øges, når Zoledronsyre Teva anvendes i kombination med thalidomid.
In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid Teva is used in combination with thalidomide.
Hos patienter med mutation udviste 4/26 (15 %) patienter forbedring i nekroinflammatorisk score og 8/26 (31 %) patienter udviste forværring sammenlignet med præ- behandling.
In patients with the mutant, 4/26 (15 %) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre- treatment.
Hos patienter med mutation udviste 4/26 (15 %) patienter forbedring i nekroinflammatorisk score og 8/26 (31 %) patienter udviste forværring sammenlignet med præ- behandling.
In patients with the mutant, 4/26 (15%) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre- treatment.
Hos patienter med mutation, udviste 4/26 (15 %) patienter forbedring i nekroinflammatorisk score og 8/26 (31 %) patienter udviste forværring sammenlignet med præ- behandling.
In patients with the mutant, 4/26 (15 %) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre- treatment.
Hos patienter med myelomatose kan risikoen for nedsat nyrefunktion øges, når intravenøse bisfosfonater anvendes i kombination med thalidomid.
In multiple myeloma patients, the risk of renal dysfunction may be increased when intravenous bisphosphonates are used in combination with thalidomide.
Hos patienter med myolodysplastiske syndromer er lenalidomid forbundet med en højere forekomst af grad 3 eller 4 neutropeni (74,6 % hos lenalidomidbehandlede patienter, sammenlignet med 14,9 % hos patienter på placebo i fase III-studiet).
In myelodysplastic syndromes patients, lenalidomide is associated with a higher incidence of grade 3 or 4 neutropenia (74.6% in lenalidomide-treated patients compared with 14.9% in patients on placebo in the Phase III study).
Hos patienter med NAGS-mangel kan behandlingen indledes allerede den første levedag, og lægemidlet anvendes igennem hele patientens levetid.
In patients with NAGS deficiency, treatment may be started as early as the first day of life and the medicine is used for the patient’s whole life.
Hos patienter med nedsat lever funktion, skal atosiban bruges med forsigtighed. (se afsnit 4.2 og 5.2).
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 5.2).
Hos patienter med nedsat leverfunktion kan insulinbehovet være nedsat på grund af nedsat evne til glukoneogenese og nedsat insulinmetabolisme.
In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Hos patienter med nedsat leverfunktion, skal atosiban bruges med forsigtighed. (se afsnit 4.2 og 4.4).
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 4.4).
Hos patienter med nedsat leverfunktion, skal atosiban bruges med forsigtighed. (se afsnit 4.2 og 4.4.)
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 4.4).
Hos patienter med nedsat leverfunktion, skal atosiban bruges med forsigtighed.(se afsnit 4.2 og 5.2).
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 5.2).
Hos patienter med nedsat leverfunktion. der skyldes neoplastisk leverpåvirkning, var total plasmaclearance ca. halveret, sammenlignet med patienter uden nedsat leverfunktion.
In patients with hepatic impairment due to neoplastic liver involvement, total plasma clearance was approximately halved compared to patients without hepatic impairment.
Hos patienter med nedsat nyrefunktion (kreatininclearance < 10 ml/min) versus raske forsøgspersoner fandtes ingen signifikant forskel i den gennemsnitlige eliminationshalveringstid (37,7 versus
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus
Hos patienter med nedsat nyrefunktion (kreatininclearance < 10 ml/min) versus raske forsøgspersoner fandtes ingen signifikant forskel i den gennemsnitlige eliminationshalveringstid (37,7 versus
In renally impaired patients (creatinine clearance <10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hrs) or clearance (21.2 versus
Hos patienter med nedsat nyrefunktion bør den maksimale daglige dosis være 18 mg.
In patients with renal impairment, the maximum daily dose should be 18 mg.
Hos patienter med nedsat nyrefunktion kan thiazid medføre azotæmi.
Thiazide diureticassociated azotaemia may occur in patients with impaired renal function.
Hos patienter med nedsat nyrefunktion kan udskillelsen af dabigatran være forlænget.
Clearance of dabigatran in patients with renal insufficiency may take longer.
Hos patienter med nedsat nyrefunktion var den renale clearance af enkeltdoser af zonisamid positivt korreleret til creatininclearance.
In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance.
Hos patienter med nedsat nyrefunktion vil clearance af gadoversetamid være forsinket, og interferens i måling af calcium ved brug af OCP vil væreforlænget.
In patients with compromised renal function, clearance of gadoversetamide will be slowed and the interference with calcium determination by OCP prolonged.
Hos patienter med nedsat nyrefunktion, som får CellCept og ganciclovir, eller dets prodrugs, f.eks. valganciclovir samtidig, bør dosisanbefalingerne for ganciclovir følges og patienterne bør monitoreres omhyggeligt.
In patients with renal impairment in whom CellCept and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered, the dose recommendations for ganciclovir should be observed and patients should be monitored carefully.